Pfizer joins the TriNetX network to ‘harness’ real world data

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/littlehenrabi)
(Image: Getty/littlehenrabi)
Pfizer will recruit patients with rare diseases and identify clinical trial sites with support from the TriNetX global health research network, which is becoming "the defacto platform" for research, says CEO.

As a network member, Pfizer gains access to data from various global healthcare organizations. The platform provides users with de-identified patient data integrated from EMRs, tumor registries, unstructured pathology reports, and molecular genomics data to support clinical study and protocol design, as well as site identification and patient recruitment.

“TriNetX is becoming the defacto platform for clinical research,”​ said Gadi Lachman, CEO of TriNetX.

The company’s global health research network includes more than 70 healthcare organizations globally. Currently, TriNetX is working with more than 25 of the top pharmaceutical companies, Lachman examined.

Dr. Mohanish Anand, head of study optimization at Pfizer said the company joined TriNetX “to harness real world data for clinical trial optimization, with the goal of accelerating our ability to bring new therapies to market.”

“Pfizer will use the real-time access to clinical, genomic and oncology data to design clinical trial protocols with greater efficiency. For example, we hope to reduce avoidable amendments by identifying and correcting overly restrictive inclusion and exclusion criteria early in the design process,”​ Anand explained in a press release.

TriNetX recently announced a new algorithm designed to further support clinical trial patient identification. The chemotherapy lines of treatment identification algorithm is able to understand treatment patterns, according to the company, which announced the new offering at the SCOPE Summit in February.

“We remain focused on developing new features and functionality to drive clinical trial optimization,”​ Lachman added.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars